Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 4 studies | 35% ± 6% |
Insufficient scRNA-seq data for expression of SLC25A47 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 21068.94 | 226 / 226 | 85% | 141.57 | 344 / 406 |
kidney | 100% | 92.76 | 89 / 89 | 4% | 0.09 | 39 / 901 |
thymus | 87% | 8.86 | 568 / 653 | 14% | 0.47 | 84 / 605 |
uterus | 87% | 5.76 | 148 / 170 | 3% | 0.05 | 12 / 459 |
pancreas | 84% | 6.49 | 277 / 328 | 3% | 0.10 | 5 / 178 |
lung | 80% | 5.05 | 460 / 578 | 1% | 0.03 | 14 / 1155 |
prostate | 78% | 4.27 | 191 / 245 | 1% | 0.06 | 4 / 502 |
intestine | 72% | 6.85 | 698 / 966 | 5% | 0.73 | 24 / 527 |
spleen | 75% | 25.04 | 181 / 241 | 0% | 0 | 0 / 0 |
adipose | 74% | 7.37 | 896 / 1204 | 0% | 0 | 0 / 0 |
adrenal gland | 73% | 3.93 | 188 / 258 | 1% | 0.02 | 2 / 230 |
stomach | 67% | 3.13 | 239 / 359 | 5% | 0.18 | 14 / 286 |
ovary | 67% | 3.69 | 121 / 180 | 2% | 0.04 | 8 / 430 |
breast | 68% | 5.23 | 311 / 459 | 1% | 0.08 | 14 / 1118 |
brain | 67% | 3.52 | 1777 / 2642 | 0% | 0.01 | 3 / 705 |
esophagus | 66% | 3.49 | 956 / 1445 | 1% | 0.02 | 2 / 183 |
peripheral blood | 63% | 23.80 | 583 / 929 | 0% | 0 | 0 / 0 |
bladder | 57% | 3.29 | 12 / 21 | 2% | 0.03 | 10 / 504 |
muscle | 57% | 2.46 | 458 / 803 | 0% | 0 | 0 / 0 |
heart | 57% | 2.47 | 487 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 55% | 2.88 | 732 / 1335 | 0% | 0 | 0 / 0 |
skin | 53% | 2.71 | 950 / 1809 | 0% | 0.03 | 2 / 472 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006810 | Biological process | transport |
GO_0015876 | Biological process | acetyl-CoA transport |
GO_0035352 | Biological process | NAD transmembrane transport |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0005743 | Cellular component | mitochondrial inner membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0022857 | Molecular function | transmembrane transporter activity |
GO_0051724 | Molecular function | NAD transmembrane transporter activity |
GO_0008521 | Molecular function | acetyl-CoA transmembrane transporter activity |
Gene name | SLC25A47 |
Protein name | Solute carrier family 25 member 47 (Hepatocellular carcinoma down-regulated mitochondrial carrier protein) (Mitochondrial NAD(+) transporter SLC25A47) Solute carrier family 25 member 47 |
Synonyms | HDMCP HMFN1655 C14orf68 |
Description | FUNCTION: Mitochondrial NAD(+) transporter that acts as a 'metabolic gate' in hepatic lipogenesis. Provides NAD(+) substrate to mitochondrial SIRT3 deacetylase and enables its NAD(+)-dependent activities in mitochondrial energy metabolism. This triggers downstream activation of PRKAA1/AMPK-alpha signaling cascade that negatively regulates sterol regulatory element-binding protein (SREBP) transcriptional activities and ATP-consuming lipogenesis to restore cellular energy balance. May transport other mitochondrial metabolites having an aromatic nucleotide and phosphate groups, such as acetyl-CoA. Does not transport amino acids. The transport mechanism remains to be elucidated. . |
Accessions | ENST00000557052.1 G3V374 Q6Q0C1 ENST00000361529.5 [Q6Q0C1-1] |